AVEO PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Net loss
Operating activities
Net income (loss)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Non-cash interest expense
Non-cash change in fair value of PIPE Warrant liability
PIPE Warrants
Total non-cash change in fair value of PIPE Warrant liability
Non-cash charge for settlement costs (Note 13)
Amortization of premium and discount on investments
Changes in operating assets and liabilities:
Insurance recovery (Note 13)
Trade receivables, net
Partnership receivables
Inventory
Prepaid expenses and other current assets
Operating lease right-of-use asset
Other non-current assets
Accounts payable
Accrued clinical trial costs and contract research
Employee Benefits and Share-based Compensation
Other accrued liabilities
Settlement liability (Note 13)
Operating lease liability
Deferred revenue
Deferred research and development reimbursements

Net cash used in operating activities
Operating lease liability, non-current

Net cash used in operating activities
Investing activities
Purchases of marketable securities
Proceeds from maturities and sales of marketable securities
Purchases of property and equipment
Net cash used in investing activities
Net cash (used in) provided by investing activities

Financing activities
Proceeds from issuance of common stock and warrants, net of issuance costs
Proceeds from issuance of loan payable and warrants
Proceeds from issuance of common stock and warrants to related parties
Proceeds from warrant exercises
PIPE Warrants
Total proceeds from warrant exercises

Proceeds from issuance of stock for stock-based compensation arrangements
Proceeds from issuance of loan payable
Payment on principal of loan payable (Note 6)
Payment of loan maturity fees (Note 6)
Payments of debt issuance costs
Net cash provided by (used in) financing activities
Payment of debt issuance costs
Net cash provided by financing activities

Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental cash flow information
Cash paid for interest
Right-of-use asset obtained in exchange for operating lease liabilities
Increase to deferred revenue due to adoption of ASC 606 - transition adjustment on January 1, 2018
Fair value of warrants issued in connection with a class action settlement (Note 13)

Comments